BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

fda_logo

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks. These events refer to reviews and decisions by the U.S. Food ...
Read Full Story »
Ebola Virus

Ebola Stock Short Interest Surprise

Fears of Ebola seem to have petered out at the end of October and into November. Some of the related stocks had been heavily shorted as they were considered by ...
Read Full Story »
Ebola Virus

New Ebola Fears in NYC Make Major Ebola Stock Waves (Updated)

Just when you thought the Ebola virus outbreak risk was dwindling down... Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all ...
Read Full Story »
Ebola Virus

Ebola Stock Fallout Severe on Monday

Is the Ebola scare over in the United States? Probably not by a long shot. That being said, Ebola fears are subsiding on Monday as dozens of people came off ...
Read Full Story »
research

Ebola Drug Stocks React Wildly to Dallas Patient Death

The sad news that Ebola patient Thomas Eric Duncan has died in Dallas' Texas Health Presbyterian hospital now raises fears that Ebola drugs might not be a cure-all for patients. ...
Read Full Story »
downgrade sign

Reality Sets in for Ebola Drug Hopefuls

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), along with other biotechs Sarepta Therapeutics Inc. (NASDAQ: SRPT) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), took a hit in the market Monday after an analyst ...
Read Full Story »
research

Major Fallout Stocks After Confirmed Ebola Case in United States

Tuesday brought the very unfortunate news that a confirmed case of Ebola has arrived in the United States. With the CDC not releasing enough data on the patient, there could ...
Read Full Story »
Comfortable hospital bed

Reaction to Confirmed Ebola Case in U.S. — UPDATED

News has hit of the first confirmed Ebola case in the United States. While this news is still breaking and developing, it appears to be a case that was after ...
Read Full Story »
research

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

After being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn't stop the ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and More

Stocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now that investors have an opportunity to look for stocks that have ...
Read Full Story »
biotech

Should Investors Really Be Chasing Potential Ebola Treatments?

The world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AMD, Dish Network, Facebook, Nordstrom, SunPower and More

It is Monday and stocks are looking for direction after new highs last week. Investors and traders now being told that the bull market has become a stock picker's market. 24/7 ...
Read Full Story »
Biotechnology word cloud

After Idenix: The Next Four Biotech Buyout Candidates

Wall Street likes nothing better than to start the week off with a bang, and pharmaceutical giant Merck & Co. Inc. (NYSE: MRK) rang the bell Monday by spending $3.85 ...
Read Full Story »
biotech

BioCryst Crushes It on Rare Immune Disorder Drug Trial

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema (HAE) met the primary efficacy endpoint, several secondary endpoints and ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Apple, BioCryst, Dow Chemical, Sanmina, Sally Beauty and More

It is another earnings season Tuesday, and analysts and investors are continuing to make adjustments to their 2014 outlook. Last week's market volatility added another wrench in the machine. 24/7 ...
Read Full Story »